Bank Julius Baer & Co. Ltd Zurich Raises Position in Medtronic PLC $MDT

Bank Julius Baer & Co. Ltd Zurich raised its stake in Medtronic PLC (NYSE:MDT) by 1.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 999,638 shares of the medical technology company’s stock after purchasing an additional 18,264 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Medtronic were worth $96,225,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Medtronic by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock worth $12,388,027,000 after purchasing an additional 1,888,381 shares during the last quarter. State Street Corp raised its stake in shares of Medtronic by 1.0% in the third quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock worth $5,800,550,000 after purchasing an additional 625,992 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Medtronic by 0.9% in the third quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock worth $2,044,637,000 after purchasing an additional 192,410 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Medtronic by 0.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after purchasing an additional 98,220 shares during the last quarter. Finally, Raymond James Financial Inc. raised its stake in shares of Medtronic by 3.0% in the third quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company’s stock worth $1,067,055,000 after purchasing an additional 327,899 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.26% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic hired a new chief operations and supply chain officer, a move that could help execution and manufacturing efficiency over time. Medtronic hires chief operations and supply chain officer
• Positive Sentiment: Brokerage coverage remains constructive, with Medtronic receiving a consensus “Moderate Buy” and multiple recent buy-equivalent ratings, which can help support the shares. Medtronic PLC (NYSE:MDT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
• Positive Sentiment: Recent updates around Medtronic’s cardiac technology and its collaboration with Orchestra BioMed suggest ongoing pipeline momentum, which may improve long-term growth expectations. Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
• Neutral Sentiment: Several articles mainly discuss why the stock has been trending and how investors are reassessing valuation after recent weakness, but they do not introduce a new fundamental catalyst. Assessing Medtronic (MDT) Valuation After Recent Share Price Weakness
• Neutral Sentiment: Orchestra BioMed’s BACKBEAT trial update is constructive for the partnership, but the key readout is not expected until 2027, so the near-term stock impact may be limited. Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
• Negative Sentiment: Recent reports also point to continued share-price weakness, with Medtronic down sharply over the past month and quarter, reflecting caution around growth and execution. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note
• Negative Sentiment: News that Medtronic is closing a California site may raise concerns about restructuring costs or operational disruption, adding to investor caution. Medtronic to close California site

Medtronic Price Performance

Shares of NYSE MDT opened at $76.19 on Thursday. The stock has a fifty day simple moving average of $85.55 and a two-hundred day simple moving average of $93.88. Medtronic PLC has a 1-year low of $74.40 and a 1-year high of $106.33. The firm has a market cap of $97.81 billion, a price-to-earnings ratio of 21.22, a price-to-earnings-growth ratio of 1.83 and a beta of 0.62. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same period in the prior year, the company earned $1.38 earnings per share. Medtronic’s revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts anticipate that Medtronic PLC will post 5.57 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.7%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s dividend payout ratio is 79.11%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MDT. Evercore set a $106.00 price target on Medtronic and gave the company an “outperform” rating in a research report on Thursday, April 9th. Robert W. Baird increased their price target on Medtronic from $92.00 to $93.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $120.00 price target on shares of Medtronic in a research report on Thursday, March 26th. Mizuho decreased their price target on Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Finally, Barclays increased their price target on Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, April 1st. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $107.80.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).